Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
OneSource Specialty PharmaNSE:ONESOURCE -2.14%8 Days Payable is 240.15 as of Jun. 2026, which is 29% below its 10-year median of 340.45. GuruFocus rates NSE:ONESOURCE with a GF Score™ of 8/100. The stock has 3 warning signs investors should review. Among 706 Biotechnology companies, OneSource Specialty Pharma ranks better than 65.01% on this metric.
The historical rank and industry rank for OneSource Specialty Pharma's Days Payable or its related term are showing as below:
NSE:ONESOURCE'
s Days Payable Range Over the Past 10 Years
Min: 107.62 Med: 340.45 Max: 1695.62
Current: 204.4
During the past 4 years, OneSource Specialty Pharma's highest Days Payable was 1695.62. The lowest was 107.62. And the median was 340.45.
NSE:ONESOURCE's Days Payable is ranked better than 65.01% of 706
companies
in the Biotechnology industry
Industry Median: 110.85
vs NSE:ONESOURCE: 204.40
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:ONESOURCE vs VRTX, REGN, RVMD: Days Payable Comparison
For the Biotechnology subindustry, OneSource Specialty Pharma's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
OneSource Specialty Pharma Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, OneSource Specialty Pharma's Days Payable distribution charts can be found below:
* The bar in red indicates where OneSource Specialty Pharma's Days Payable falls into.
OneSource Specialty Pharma Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OneSource Specialty Pharma (NSE:ONESOURCE) has a Days Payable of 240.15 as of Jun. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on OneSource Specialty Pharma and its competitors. This is 29% below median its historical median of 340.45. Over the past decade, OneSource Specialty Pharma's Days Payable has ranged from 107.62 to 1,695.62. According to the industry distribution chart, OneSource Specialty Pharma ranks #247 out of 706 companies in the Biotechnology industry, placing it in the top 35%.
Is OneSource Specialty Pharma's Days Payable too high?
OneSource Specialty Pharma's current Days Payable of 240.15 is 29% below median its 10-year median of 340.45. Over the past 10 years, this metric has ranged from a low of 107.62 to a high of 1,695.62. The Biotechnology industry median Days Payable is 110.85. OneSource Specialty Pharma's value of 240.15 is 116.6% above this industry median. Based on the distribution chart, OneSource Specialty Pharma ranks #247 out of 706 companies in the Biotechnology industry, which is above the industry midpoint. Overall, OneSource Specialty Pharma has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does OneSource Specialty Pharma's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, OneSource Specialty Pharma ranks #247 out of 706 companies for Days Payable. This puts OneSource Specialty Pharma in the upper half of its industry. The industry median Days Payable is 110.85. OneSource Specialty Pharma's value of 240.15 is 116.6% above this benchmark. Historically, OneSource Specialty Pharma's own Days Payable has ranged from 107.62 to 1,695.62 over the past decade. While the company's 10-year median is 340.45 vs. the industry median of 110.85, OneSource Specialty Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 110.85, based on 706 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. OneSource Specialty Pharma's current Days Payable of 240.15 is 116.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on OneSource Specialty Pharma and its competitors. For the Biotechnology industry, the median Days Payable is 110.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. OneSource Specialty Pharma's current Days Payable is 240.15, which is 29% below median its own 10-year median of 340.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OneSource Specialty Pharma stock overvalued right now?
OneSource Specialty Pharma (NSE:ONESOURCE) has a current Days Payable of 240.15. The current Days Payable is 240.15, which is 29% below median its 10-year median of 340.45 and 116.6% above the Biotechnology industry median of 110.85. OneSource Specialty Pharma's overall GF Score™ is 8/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For OneSource Specialty Pharma (NSE:ONESOURCE), the current Days Payable is 240.15 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
OneSource Specialty Pharma Ltd is engaged in the research, development, manufacture and commercialization of biological drug products in different injectable formats. The company also offers end-to-end CDMO services across all phases of pre-clinical and clinical development and commercial supply of biologics. The company's reportable segments are CDMO (Contract Development and Manufacturing Organization (CDMO) : Development and manufacture of pharmaceutical products and associated services); and Unit-3 Multimodal Facility and CDMO-2.
8GF Score
Get the complete analysis for NSE:ONESOURCE
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ONESOURCE has been successfully added to your 
